Upstream anticoagulation: Another brick in the wall?

Abstract

Key Points There is no clear consensus regarding the optimal drug and timing of the anticoagulation therapy in primary percutaneous coronary intervention (PCI). Upstream anticoagulation therapy would appear to have advantages for patients, both from the ischemic standpoint and from the bleeding one. Future trials are needed to compare different possible strategies with anticoagulation therapies, regarding both the timing and the optimal drug for ST‐elevation myocardial infarction patients.